2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-179029
    RNA polymerase-IN-4 3040910-48-0 98%
    RNA polymerase-IN-4 is a RNA polymerase inhibitor with an EC50 of 22.81 nM. RNA polymerase-IN-4 exhibits potent anti-influenza virus activity (EC50 = 3.76 nM), relatively low cytotoxicity (CC50 = 29.91 μM). RNA polymerase-IN-4 can be used for the research of infection, such as influenza virus infection.
    RNA polymerase-IN-4
  • HY-179038
    PYO12 433702-41-1
    PYO12 is a 3-phenyl-4-phenoxypyrazole type antibacterial compound. PYO12 exhibits selective activity against Gram-positive bacteria with MIC for S. aureus, B. subtilis, S. pneumoniae, and MRSA of 1, 1, 1, and 4 μg/mL respectively. PYO12 has no activity against Gram-negative bacteria. PYO12 can significantly increase bacterial membrane permeability and significantly upregulate cell wall stress-related genes, possibly by binding to the C55-PP part of lipid II. PYO12 shows a concentration-dependent bactericidal effect, has low toxicity to mammalian cells, and does not cause hemolysis. PYO12 can be used to develop new antibiotics targeting bacterial cell wall synthesis.
    PYO12
  • HY-179048
    MH44 2766190-68-3
    MH44 is an efficient inhibitor targeting the SARS-CoV-2 nsp14 N7-methyltransferase (N7-MTase) with an IC50 of 19 nM. MH44 exhibits moderate antiviral effects in SARS-CoV-2-infected A549-hACE2 cells and shows certain cytotoxicity at higher concentrations. MH44 can be used in the research on anti-SARS-CoV-2.
    MH44
  • HY-179059
    Anti-MRSA agent 40 98%
    Anti-MRSA agent 40 (Compound 7-8) is a potent agent against Methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 40 exhibits significant antibacterial activity against MRSA2 and S. aureus ATCC 29213, with its MIC values being 1 μg/mL. Anti-MRSA agent 40 causes depolarization of the cell membrane, damages membrane integrity, and simultaneously increases the level of ROS within MRSA2, ultimately leading to cell lysis and death. Anti-MRSA agent 40 shows significant efficacy in the MRSA2 skin abscess model. Anti-MRSA agent 40 can be used for research on anti-MRSA infections.
    Anti-MRSA agent 40
  • HY-179097
    SARS-CoV-2 nsp14-IN-8 98%
    SARS-CoV-2 nsp14-IN-8 (Compound 26) is a SARS-CoV-2 nsp14 inhibitor, with an IC50 of 53 nM. SARS-CoV-2 nsp14-IN-8 shows IC50 values of 170 nM, 8 nM, 21 nM against SARS-CoV-1 nsp14, HCoV-NL63 nsp14, HCoV-229E nsp14, respectively. SARS-CoV-2 nsp14-IN-8 can be used in the research of Coronavirus infection.
    SARS-CoV-2 nsp14-IN-8
  • HY-179102
    SARS-CoV-2 Mpro-IN-51 2648754-84-9 98%
    SARS-CoV-2 Mpro-IN-51 (compound 4) is a SARS-CoV-2 Mpro inhibitor (IC50 = 26 nM). SARS-CoV-2 Mpro-IN-51 has inhibitory effects on the triple mutant L50F/E166A/L167F. SARS-CoV-2 Mpro-IN-51 can be used for research on viral infections.
    SARS-CoV-2 Mpro-IN-51
  • HY-179104
    LasB-IN-2
    LasB-IN-2 (Compound 12) is a selective LasB inhibitor, with a Ki of 0.92 μM. LasB-IN-2 shows antibiofilm activity. LasB-IN-2 can be used in the research of bacterial infections, including Pseudomonas aeruginosa.
    LasB-IN-2
  • HY-179116
    BL-1005 98%
    BL-1005 (BS2463), thiophen-2-yl pyrimidine (TTP), is a potent paralytic of Schistosoma mansoni with an EC50 of 37 nM. BL-1005 shows low cytotoxicity for HEK293, HeLa and HepG2 cell with CC50 >20 μM. BL-1005 can induce paralysis in both adult and juvenile S. mansoni. BL-1005 can be used for the research of infection.
    BL-1005
  • HY-179118
    Antimalarial agent 53 98%
    Antimalarial agent 53 (compound 31) is an antimalarial agent. Antimalarial agent 53 blocks protein synthesis by inhibiting the cytoplasmic ribosomes of malaria parasites, exhibiting potent antimalarial activity (IC50 = 3.9 nM) and good selectivity. Antimalarial agent 53 has no cross resistance and good safety. Antimalarial agent 53 can be used for research on malaria.
    Antimalarial agent 53
  • HY-179120
    ZJS178 3095661-21-2
    ZJS178 is a novel inhibitor of myosin I. ZJS178 is a fungicide that has inhibitory activity against Fusarium graminearum and can reduce DON toxin synthesis. ZJS178 can be used for research on plant diseases such as wheat scab.
    ZJS178
  • HY-179127
    Carbonic anhydrase-IN-36
    Carbonic anhydrase-IN-36 (Compound 5p) is a MtCA 3 inhibitor with a Ki of 0.07 µM against MtCA 3. Carbonic anhydrase-IN-36 inhibits the β-class enzyme MtCA 3. Carbonic anhydrase-IN-36 demonstrates potent antimycobacterial activity, with an MIC of 8 µg/mL against Mtb. Carbonic anhydrase-IN-36 retains activity against Rifampicin (HY-B0272)-resistant M. tuberculosis.
    Carbonic anhydrase-IN-36
  • HY-179138
    CYP51-IN-28 98%
    CYP51-IN-28 (compound B9) is a CYP51 inhibitor. CYP51-IN-28 is an efficient, broad-spectrum, and low toxicity antifungal molecule. CYP51-IN-28 can be used for research on fungal infections.
    CYP51-IN-28
  • HY-179139
    SDH-IN-40 98%
    SDH-IN-40 (compound A7) is a succinate dehydrogenase inhibitor (SDHI). SDH-IN-40 exhibits strong inhibitory effects on F. graminearum (IC50 = 34.33 μM). SDH-IN-40 can be used for research on fungal infections.
    SDH-IN-40
  • HY-179163
    CYP51-IN-29
    CYP51-IN-29 (Compound B3) is a CYP51 inhibitor and antifungal agent. CYP51-IN-29 effectively suppresses the yeast-to-hyphal transition. CYP51-IN-29 exhibits potent antifungal activity against Candida albicans.
    CYP51-IN-29
  • HY-179220
    HIV-1-IN-88 2459707-59-4
    HIV-1-IN-88 (compound 20a) is a potent HIV‑1 protease inhibitor (IC50 = 10 pM) with an antiviral EC50 of 10.4 nM. HIV-1-IN-88 exhibits potency against the multidrug-resistant variants HIV-1Muta and HIV-1I50V with EC50 values of 30.0 and 34.3 nM, respectively. HIV-1-IN-88 can be used for HIV research.
    HIV-1-IN-88
  • HY-179221
    HIV-1-IN-89
    HIV-1-IN-89 (Compound 20a-D) is a prodrug of 20a (an HIV-1 protease inhibitor). HIV-1-IN-89 has better pharmacokinetic properties. HIV-1-IN-89 can be used for studying the resistance to HIV-1.
    HIV-1-IN-89
  • HY-179270
    CYP51-IN-30 108590-84-7
    CYP51-IN-30 is a CYP51 inhibitor and fungicidal agent. CYP51-IN-30 inhibits CYP51 activity. CYP51-IN-30 displays potent fungicidal activity with an EC50 value of 2.97 mg/L against S. sclerotiorum.
    CYP51-IN-30
  • HY-179273
    Proteasome-IN-8 3097658-48-2 98%
    Proteasome-IN-1 (Compound 130) is a proteasome inhibitor. Proteasome-IN-1 exhibits antiparasitic activity against P. faciparum 3D7.
    Proteasome-IN-8
  • HY-179281
    MsbA-IN-7
    MsbA-IN-7 (Compound 12) is a MsbA inhibitor and antibacterial agent. MsbA-IN-7 shows antibacterial activity.
    MsbA-IN-7
  • HY-179287
    SDH-IN-42 98%
    SDH-IN-42 (Compound D28) is a SDH (IC50: 5.38 μg/mL) inhibitor and antifungal agent. SDH-IN-42 exerts antifungal activity against R. solani by disrupting mycelial morphology, increasing cell membrane permeability, inducing the production and accumulation of ROS, and impairing mitochondrial function.
    SDH-IN-42
Cat. No. Product Name / Synonyms Application Reactivity